T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...
Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two...
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D o...
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant...
SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gast...
Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announced the expansion...
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 Sanofi announced that it has entered in...
Wasatch BioLabs (WBL), a leader in native, long-read sequencing and epigenomic analysis, announced a co-marketing agreement with Agilent Technologies to ...
T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligon...
Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program Agreement Provides Tariff Re...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the Priority Review Voucher scheme is a lifeline for...
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly...
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psor...
© 2026 Biopharma Boardroom. All Rights Reserved.
